# Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients

> **NCT03686202** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 65 (estimated)

## Conditions studied

- All Solid Tumors

## Interventions

- **BIOLOGICAL:** MET-4

## Key facts

- **NCT ID:** NCT03686202
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-30
- **Primary completion:** 2024-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03686202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03686202, "Feasibility Study of MET-4: Evaluating Fecal Microbiome Effects in Immunotherapy Patients". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03686202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*